Jazz Pharmaceuticals plc, of Dublin, said, through its wholly owned subsidiary Jazz Investments I Ltd., is offering $500 million aggregate principal amount of 1.5 percent exchangeable senior notes due 2024 in a private offering to qualified institutional buyers.